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SUMMARY

Naive human embryonic stem cells (hESCs) have been isolated that more closely resemble the pre-implantation epiblast compared to conventional ‘‘primed’’ hESCs, but the signaling principles underlying these
discrete stem cell states remain incompletely understood. Here, we describe the results from a highthroughput screen using 3,000 well-annotated compounds to identify essential signaling requirements
for naive human pluripotency. We report that MEK1/2 inhibitors can be replaced during maintenance of naive
human pluripotency by inhibitors targeting either upstream (FGFR, RAF) or downstream (ERK1/2) kinases.
Naive hESCs maintained under these alternative conditions display elevated levels of ERK phosphorylation
but retain genome-wide DNA hypomethylation and a transcriptional identity of the pre-implantation epiblast.
In contrast, dual inhibition of MEK and ERK promotes efficient primed-to-naive resetting in combination with
PKC, ROCK, and TNKS inhibitors and activin A. This work demonstrates that induction and maintenance of
naive human pluripotency are governed by distinct signaling requirements.
INTRODUCTION
A major objective in stem cell research is to devise in vitro culture
conditions for pluripotent stem cells (PSCs) that recapitulate
specific stages of embryonic development. The use of MEK
and GSK3 inhibitors and leukemia inhibitory factor (2i/LIF) captures mouse embryonic stem cells (ESCs) in a ‘‘naive’’ state of
pluripotency that closely corresponds to the pre-implantation
epiblast at embryonic day (E) 4.5 (Boroviak et al., 2015; Ying
et al., 2008). This naive state of pluripotency contrasts with the
‘‘primed’’ pluripotent state observed in mouse epiblast stem
cells (EpiSCs), which aligns more closely with the anterior primitive streak of the late-gastrula stage embryo (Brons et al., 2007;
Kojima et al., 2014; Tesar et al., 2007). Overlapping biological
and molecular features between human PSCs (hPSCs) and
mouse EpiSCs lend support to the notion that hPSCs adopt a
primed pluripotent identity when derived under conventional
conditions (Nichols and Smith, 2009). Indeed, transcriptome
profiling of primate embryos confirmed that conventional hPSCs
most closely correlate with the late post-implantation epiblast
(Nakamura et al., 2016). Nevertheless, recent work indicates
that a subpopulation of conventional hPSCs with high selfrenewal capacity displays properties more aligned with the early

post-implantation epiblast (Cornacchia et al., 2019; Lau et al.,
2020). Conventional hPSCs also exhibit some primate-specific
features that are not observed in either mouse ESCs or EpiSCs,
such as expression of N-cadherin at colony boundaries (Nakanishi et al., 2019).
Over the past decade, a number of groups have attempted to
induce features of naive pluripotency in hPSCs using chemical
and genetic approaches (Chan et al., 2013; Gafni et al., 2013;
Hanna et al., 2010; Takashima et al., 2014; Theunissen et al.,
2014; Ware et al., 2014; Zimmerlin et al., 2016). Based on comparisons to single cell RNA sequencing (scRNA-seq) data from
human and non-human primate embryos (Huang et al., 2014;
Nakamura et al., 2016; Stirparo et al., 2018), naive cells derived
in two specific culture conditions display particularly strong transcriptional signatures of the pre-implantation embryo: t2i/L/Gö,
which consists of titrated 2i/LIF and a PKC inhibitor (Takashima
et al., 2014), and 5i/L/A, which consists of MEK, GSK3, BRAF,
SRC, and ROCK inhibitors together with LIF and activin A (Theunissen et al., 2014). Naive hPSCs have provided a cellular
model system to investigate human-specific mechanisms of X
chromosome regulation (Sahakyan et al., 2017; Vallot et al.,
2017) and the role of transposable elements (TEs) that are associated with early embryogenesis (Pontis et al., 2019; Theunissen
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Figure 1. High-throughput chemical screening for modulators of naive human pluripotency in minimal conditions
(A) Experimental strategy for identifying compounds that maintain naive human pluripotency in the presence or absence of MEK1/2 and GSK3 inhibitors (2i) using
WIBR3 OCT4-DPE-GFP+ naive hESCs (Theunissen et al., 2014).
(B) Multi-parametric data analysis (MPDA) from a representative 384-well plate analyzed in two biological replicates showing the activity of small molecules with
respect to active controls (AC, +DOX) and negative controls (NC, –DOX) based on high-content imaging.
(C) Pie charts summarizing the target classes of validated hit compounds in N2B27 medium supplemented with Y-27632 alone (N2B27/Y) (left), XAV939 and Y27632 (XAV/Y) (middle), and Gö6983 and Y-27632 (Gö/Y) (right). Hit compounds were validated in two biological replicates. The scale bar depicts 260 mm.

(legend continued on next page)
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et al., 2016). In addition, recent findings indicate that these cells
also harbor the ability to acquire extraembryonic fates (Cinkornpumin et al., 2020; Dong et al., 2020; Guo et al., 2021; Io et al.,
2021; Linneberg-Agerholm et al., 2019) and give rise to human
blastocyst-like structures (Yu et al., 2021).
Despite the progress cited above, important questions
remain about the nature of human pluripotent states and the
utility of naive hPSCs in regenerative medicine. Naive hPSCs
derived in t2i/L/Gö or 5i/L/A exhibit a global loss of imprinting
and extended culture in 5i/L/A leads to genomic instability
(Pastor et al., 2016; Theunissen et al., 2016). This has been
attributed to global DNA hypomethylation resulting from the
use of a MEK1/2 inhibitor, PD0325901, which is a near-universal
component of naive stem cell protocols described to date (Choi
et al., 2017; Yagi et al., 2017). While a SRC inhibitor could
replace the MEK inhibitor in mouse ESCs, it was unable to do
so in naive hPSCs (Choi et al., 2017; Yagi et al., 2017). In addition, titration of MEK inhibition was reported to enhance the
genomic stability of naive hPSCs in 5i/L/A but was not tolerated
in t2i/L/Gö, suggesting that MEK inhibition is essential for the
naive state of human pluripotency (Di Stefano et al., 2018).
Here, we performed high-throughput chemical screening to
discover alternative compounds that can maintain naive human
pluripotency in the absence of MEK1/2 inhibitors. We also
omitted GSK3 inhibition as naive hPSCs cultured in the absence
of a GSK3 inhibitor maintained a naive-specific transcriptome
(Theunissen et al., 2016). This work uncovers distinct signaling
requirements for induction and maintenance of naive human
pluripotency and provides a basis for refinement of naive culture regimes.
RESULTS
High-throughput screening identifies modulators of
naive human pluripotency in minimal conditions
Our prior study, which resulted in the identification of the 5i/L/A
cocktail, screened a library of 230 kinase inhibitors to identify
compounds that can sustain naive-specific reporter activity in
combination with 2i/LIF (Theunissen et al., 2014). Here, we
considered whether alternative modulators of naive human pluripotency may be identified by repeating this screen on a highthroughput scale and applying a dynamic chemogenetic library
of 3,000 chemical probes in which a well-defined target is
known for each of the compounds (Novartis Mechanism of Action Box) (Canham et al., 2020) either in the presence or absence
of 2i. Similar to our prior study, we used naive hESCs that were
generated with doxycycline (Dox)-inducible transgenes driving
exogenous KLF2 and NANOG transgenes (Theunissen et al.,
2014). These cells contain an endogenous OCT4 reporter allele
in which the primed-specific proximal enhancer has been
deleted (OCT4-DPE-GFP). Upon withdrawal of DOX, GFP re-
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porter activity was reduced and colony morphology was lost
within 5 days, providing a convenient time window for highthroughput screening (Figure 1A).
As a pilot experiment, we seeded 3,000 OCT4-DPE-GF
P+-naive hESCs per well in 384-well plates and removed
DOX but continued to culture the cells in the presence of 2i
and the Rho-associated kinase (ROCK) inhibitor Y-27632,
which promotes viability after single cell dissociation (Watanabe et al., 2007) (2i/Y). We omitted LIF since its removal
from established naive hESCs had little impact on naive-specific enhancer activity and gene expression (Theunissen
et al., 2014). Individual compounds were applied on days 1
and 4, and images were obtained on day 5. We designed a
multi-parametric data analysis (MPDA) algorithm to analyze
these images, computing a Mahalanobis distance score between each compound and the active (+DOX) and negative
(–DOX) control wells based on features that included area,
compactness, and fluorescence intensity of individual object
regions (Figure 1B) (see STAR Methods for details). This
enabled us to distinguish objects that were likely due to cell
death and phenotypes that were disparate from the desired
phenotype observed in the positive control wells (Figure S1A).
The screen showed good performance (Z0 = 0.6 ± 0.1), and hits
were called based on distance to the active control (+DOX)
wells. This screen identified 33 validated hit compounds that
could synergize with the 2i cocktail in maintaining naive colony
morphology and reporter activity upon removal of DOX-inducible transgenes (Figures S1B and S1C; Table S1). These hits
included several target classes that have previously been implicated in control of naive human pluripotency, such as PKC (Takashima et al., 2014), BRAF, FGFR, VEGFR (Theunissen et al.,
2014), and p38 MAPK (Gafni et al., 2013), demonstrating the
capability of our screen to identify chemical modulators of
naive human pluripotency.
We investigated whether our screening platform could be
adapted to discover alternative compounds that sustain naive
human pluripotency in the absence of 2i. OCT4-DPE-GF
P+-naive hESCs were again seeded in 384-well plates, but this
time compounds were supplemented only with Y-27632
(N2B27/Y). Pilot assays revealed that a maximal Z0 factor was obtained in absence of 2i by performing image acquisition on day 7
post-DOX withdrawal.
As expected, MEK1 inhibitors emerged as the top-ranked
category during validation assays (28%). In addition, a robust increase in GFP activity was confirmed in presence of several
tankyrase (TNKS) inhibitors, as well as inhibitors of ERK,
DNMT1, FGFR1, and SRC (Figures 1C and 1D, left panel). The
TNKS inhibitor XAV939, which showed a particularly strong effect, inhibits WNT signaling and was shown to be beneficial for
naive human pluripotency in two studies prior to this screen
(Guo et al., 2017; Zimmerlin et al., 2016). Compared to inhibition

(D ) Fluorescent images of active control (+DOX), negative control (–DOX), and selected hit compounds in N2B27/Y (left), XAV/Y (middle), and Gö/Y (right). Hit
compounds were validated in two biological replicates.
(E) Structures and CIDs of 13 commercially available hit compounds that displayed validated activity in maintaining naive human pluripotency in the three
examined basal media in the absence of 2i (Y, Gö/Y, and XAV/Y). Source: PubChem. A full list of validated hit compounds in the absence of 2i is included in Table
S2.
See also Figure S1 and Table S2.
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Figure 2. Defining the activity of selected hit compounds during extended maintenance assays for naive human pluripotency
(A) Experimental scheme for extended maintenance assays to evaluate the efficacy of hit compounds using WIBR3 OCT4-DPE-GFP+ naive hESCs derived in 5i/L/
A.
(B) Quantitative gene-expression analysis for GFP in naive hESCs that were switched from 5i/L/A to the indicated culture conditions for two passages. In this
experiment, compounds were applied at 2.5 mM concentration. Error bars indicate mean ± SD of three technical replicates. Data are representative of two
biological replicates.

(legend continued on next page)
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of MEK1, treatment with XAV939 yielded larger colonies but a
slightly dimmer OCT4-DPE-GFP signal (Figure 1D, left panel).
We then re-screened the Mechanism of Action library to identify compounds that could synergize with both XAV939 and Y27632 (XAV/Y). MEK1 again appeared as the top target class,
but we also identified and validated other hit compounds that
could synergize with TNKS inhibition, including inhibitors of
EGFR, PKC, RAF, and SRC (Figures 1C and 1D, middle panel).
PKC was an enriched target class in both our 2i/Y and XAV/Y
screens (Figure 1C; Figures S1B and S1C), which is consistent
with inclusion of the PKC inhibitor Gö6983 in the t2i/L/Gö formulation (Takashima et al., 2014). We therefore also re-screened the
Mechanism of Action library in the presence of the PKC inhibitor
Gö6983 and Y-27632 (Gö/Y). This screen identified synergy between Gö6983 and inhibitors of RAF, TGFBR2, SRC, and other
targets (Figures 1C and 1D, right panel). Excluding MEK1/2
inhibitors, our high-throughput screens identified 35 hit compounds that showed activity in maintaining naive human pluripotency in one or several of the three examined basal conditions
(Y, Gö/Y and XAV/Y) (Table S2). These compounds included inhibitors of signal transduction cascades, G-protein-coupled receptors, chromatin modifiers, cell-cycle regulators, and other
targets. In cases where multiple hit compounds converged on
the same molecular target (RAF, SRC, TGFBR, and TNKS), the
compound with greater activity was selected for follow-up
experiments.
Defining the activity of selected hit compounds during
extended naive hPSC culture
We investigated whether 13 hit compounds that could be readily
procured from commercial vendors (Figure 1E) were capable of
maintaining naive human pluripotency over multiple passages
in the absence of 2i. For this purpose, we used WIBR3
OCT4-DPE-GFP+-naive hESCs that were generated in the
absence of reprogramming transgenes using the 5i/L/A cocktail
(Theunissen et al., 2014). Naive hESCs were seeded in 6-well
plates and transferred from 5i/L/A to the 17 different 2i-independent media formulations identified in our high-throughput
screens (3/13 hits showed activity in multiple screens and were
therefore tested in multiple basal media) (Figure 1E; Table S3).
Compounds were tested at two different concentrations (2.5
and 5 mM), and cells were maintained for two passages (Figure 2A). Imaging and quantitative reverse transcriptase PCR
(qRT-PCR) analysis indicated that only 3 of these compounds
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showed significant activity in maintaining OCT4-DPE-GFP reporter activity after passaging: the ERK1/2 inhibitor GDC-0994
and the FGFR1 inhibitor PD166866 showed activity in the presence of ROCK inhibitor (Y) alone, while the pan-RAF inhibitor
AZ628 showed activity in Gö/Y and XAV/Y (Figure 2B; Figures
S2A and S2B).
We initially focused on the pan-RAF inhibitor AZ628, which
supported robust expansion of OCT4-DPE-GFP+ cells in the
presence of either XAV or Gö. We first asked whether naive
hESC self-renewal could be enhanced by combining AZ628,
XAV, Gö, and Y-27632 together in a single cocktail (AXGY).
Indeed, this combination enabled homogeneous expansion of
naive hESCs as measured by flow-cytometry analysis for the
cell-surface markers CD75 and SUSD2, which are enriched in
naive compared to primed hESCs (Bredenkamp et al., 2019a;
Collier et al., 2017), and qRT-PCR analysis for the naive-specific
transcription factor KLF17, which is expressed in the human
blastocyst (Blakeley et al., 2015) (Figures 2C, 2D, and S2C).
We then investigated whether the addition of the other hit compounds to the AXGY cocktail could further boost the expansion,
purity, and/or gene expression of naive hESCs (Figures S2D and
S2E). Notably, the SRC family kinase inhibitor Naphtol-PP1,
which scored in all three of our high-throughput screens,
enhanced dome-shaped colony morphology. A similar effect
was seen with the SRC inhibitor WH-4-023, which is included
in the 5i/L/A cocktail (Theunissen et al., 2014). However, SRC inhibition had little impact on expression of naive-specific cell-surface markers or transcript levels and was therefore not included
for further analysis. The G9a/GLP inhibitor UNC0638 further
stimulated KLF17 expression, although colony proliferation
was slightly reduced compared to AXGY (Figures S2D and S2E).
We also tested whether AZ628 could substitute for the MEK inhibitor PD03 in the 5i/L/A cocktail. This culture formulation,
which we designated as alternative 5i/L/A (a5i/L/A), maintained
a high level of OCT4-DPE-GFP activity (Figures S2F–S2H) and
enhanced the purity of CD75/SUSD2 double-positive cells
compared to 5i/L/A in both wild-type H9 and WIBR3 cells (Figure 2E; Figure S2I). However, naive hESCs maintained in AXGY
displayed markedly enhanced colony formation efficiency
compared to 5i/L/A or a5i/L/A (Figure 2E; Figure S2I). This suggests that the combination of TNKS and PKC inhibitors provides
a signaling milieu that is more conducive for naive cell expansion.
Colony formation efficiency in AXGY was more comparable to
PXGLY, which is a modified version of the t2i/L/Gö cocktail in

(C) Phase-contrast images (top) and flow-cytometry analyses using naive-specific CD75 and SUSD2 antibodies (bottom) in H9-naive hESCs that were switched
from 5i/L/A to the indicated culture conditions for two passages. The scale bar depicts 250 mm.
(D) Quantitative gene-expression analysis for the naive-specific transcription factor KLF17 in samples shown in (C). Error bars indicate mean ± SD of three
technical replicates.
(E) Phase-contrast images (top), alkaline phosphatase (AP) staining (middle), and flow-cytometry analyses using naive-specific CD75 and SUSD2 antibodies
(bottom) in H9-naive hESCs that were switched from 5i/L/A and maintained in four different naive conditions for two passages. Data are representative of two
biological replicates. The scale bar depicts 250 mm.
(F) Experimental scheme for evaluating the capacity of alternative naive maintenance conditions to maintain biallelic X-linked reporter activity using WIBR3
MECP2-GFP/tdTomato reporter hESCs.
(G) Flow-cytometry analysis for GFP and tdTomato in naive WIBR3 MECP2-GFP/tdTomato reporter hESCs that were derived from the primed state in 5i/L/A and
thereafter maintained in a5i/L/A, AXGY, or AXGYU for two passages.
(H) Western blot analysis for p-ERK, total ERK, and b-actin in H9-naive hESCs derived from the primed state in 5i/L/A and switched to PXGLY (Bredenkamp et al.,
2019b), a5i/L/A, AXGY, or AXGYU.
See also Figure S2 and Table S3.
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Figure 3. Molecular profiling of alternative naive hESCs maintained in the absence of 2i
(A) Heatmap of RNA-seq data from primed hESCs maintained in mTeSR1 and naive hESCs that were derived in 5i/L/A and subsequently maintained in 5i/L/A or
three alternative naive media (a5i/L/A, AXGY, or AXGYU) for two passages. Hierarchical clustering of Spearman’s rank correlation coefficients between samples
was performed considering significantly differentially expressed genes (DEGs) (abs(log2FC) >1.5, adj p < 0.05). Data are shown for two independent genetic
backgrounds (H9 and WIBR3 hESC lines).

(legend continued on next page)
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which GSK3 inhibition is replaced by TNKS inhibition (Bredenkamp et al., 2019a, 2019b) (Figure 2E). We also examined
whether these alternative naive conditions can maintain biallelic
expression of a dual X-linked fluorescent reporter line, which is
activated upon primed-to-naive resetting in 5i/L/A (An et al.,
2020; Theunissen et al., 2016) (Figure 2F). Indeed, a5i/L/A,
AXGY, and AXGY supplemented with the G9a/GLP inhibitor
UNC0638 (AXGYU) were all capable of maintaining MECP2GFP/tdTomato double-positive cells over two passages, suggesting that both X chromosomes remain active under these
alternative naive conditions (Figure 2G).
AZ628 is a pan-RAF inhibitor for BRAF and CRAF (RAF1)
(Wenglowsky et al., 2012). Since the RAF kinases are located upstream of MEK1/2 in the MAPK signaling cascade, we expected
that RAF inhibition should phenocopy MEK inhibition and suppress the downstream phosphorylation of ERK1/2. Surprisingly,
switching naive hESCs from 5i/L/A to the alternative naive maintenance media resulted in stimulation of phosphorylated (p)-ERK
levels (Figure 2H). This result indicates that the complete suppression of ERK phosphorylation is dispensable for maintenance
of several hallmarks of naive human pluripotency, such as robust
expression of KLF17, OCT4-DPE-GFP reporter activity, and biallelic MECP2 expression. It also suggests that the pan-RAF inhibitor AZ628 may stimulate naive human pluripotency through
mechanisms that are located upstream of ERK, such as
blockade of other RAF or MEK targets. Alternatively, the effect
of AZ628 could be mediated through inhibition of lower affinity kinase targets, which include Epha2, PDGFRA, p38 alpha, LCK,
and RET (Wenglowsky et al., 2012).
Naive hESCs maintained with a pan-RAF inhibitor retain
a pre-implantation identity
To define the transcriptional identity of naive hESCs maintained
with AZ628, we performed RNA-seq analysis on H9 and WIBR3naive hESCs that were derived in 5i/L/A and subsequently transferred to a5i/L/A, AXGY, or AXGYU. Hierarchical clustering
based on significantly differentially expressed genes (DEGs)
perfectly separated naive and primed hESCs (Figure 3A; Table
S4). Within the naive branch, the alternative naive media formed
a separate cluster from the 5i/L/A samples. Overall, all naive
conditions exhibited highly similar expression of typical naivespecific transcription factors, such as DPPA3, DPPA5, DNMT3L,
NLRP2, and KHDC3L (Figure 3B). Volcano-plot analyses indicated consistent upregulation of the ERK-responsive negative
feedback regulator SPRY1 and the transcription factor GLI2 in
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the alternative naive conditions, while the 5-methylcytosine hydroxylase TET2 and markers associated with extraembryonic
lineages (e.g., GATA6, GCM15, HAND1, KRT18, TFAP2A) were
upregulated in 5i/L/A (Figures S3A–S3C). The alternative naive
hESCs that were maintained without MEK1/2 inhibitors also
showed upregulation of the ERK-responsive genes ERG1,
SPRY2, and TCF3 (Figure 3C).
Comparison to scRNA-seq analysis of 3D-cultured human
embryos (Xiang et al., 2020) segregated 5i/L/A and the alternative naive conditions into two distinct clusters: while 5i/L/A samples were more closely aligned with the inner cell mass (ICM) at
days 6–7 of human development, naive hESCs maintained in
AXGY, AXGYU, or a5i/L/A clustered more closely with pre-implantation epiblast (EPI) cells at days 7–8 of development (Figure 3D). In contrast, primed hESCs in mTeSR media aligned
more closely with post-implantation EPI cells at days 12–14 of
development, which is consistent with a prior comparison to
non-human primate embryos (Nakamura et al., 2016). These
data indicate that naive hESCs maintained with the pan-RAF inhibitor AZ628 reside in a more advanced stage of human EPI
development yet retain expression of typical marker genes associated with naive human pluripotency.
Since naive and primed hESCs can be distinguished by
expression of developmentally programmed TE families (Pontis
et al., 2019; Theunissen et al., 2016), we also examined the transposon transcription profile or ‘‘transposcriptome’’ under alternative naive conditions. Naive cells in 5i/L/A showed elevated
expression of the LTR7B TE subfamily, while transfer to AXGY,
AXGYU, or a5i/L/A resulted in a moderate increase in expression
of LTR7 and HERVH integrants (Figures 3E–3G and S3D), which
were previously shown to be upregulated in primed hESCs (Theunissen et al., 2016). This effect was most pronounced upon
addition of the G9a/GLP inhibitor UNC0638. However, the activation of LTR7 and HERVH elements was far more extensive
and significant in primed hESCs, which indicates that LTR7/
HERVH expression is dynamic across different stages of EPI
development captured in vitro. In contrast, expression of
naive-enriched SVA-D and HERVK integrants was largely invariable between 5i/L/A and the alternative naive conditions (Figures
S3E and S3F). These data provide a further confirmation that full
suppression of ERK phosphorylation is dispensable for maintaining key hallmarks of naive human pluripotency.
Globally reduced DNA methylation levels are an intrinsic
feature of mammalian pre-implantation development that is
recapitulated in naive stem cell culture (Hackett et al., 2013;

(B) Expression heatmap of selected naive and primed-specific markers in the samples described in (A).
(C) Expression heatmap of selected ERK-responsive target genes in the samples described in (A).
(D) UMAP dimension reduction analysis of single cell RNA-seq data representing ICM, Pre-EPI, and Post-EPI from 3D-cultured human embryos (Xiang et al.,
2020) compared to the naive and primed samples described in (A). Clusters are drawn to indicate in vivo samples as shown in Xiang et al. (2020).
(E) TE families upregulated in 5i/L/A (p-ERKLOW UP) versus three alternative naive maintenance conditions (p-ERKHIGH UP). Histograms indicate the percentages
of TE copies that are upregulated by logFC >2 in either sample group.
(F) Heatmap indicating differentially expressed TE families between naive H9 and WIBR3 hESCs maintained in 5i/L/A or three alternative naive maintenance
conditions.
(G) Heatmap indicating expression of individual HERVH integrants in primed H9 and WIBR3 hESCs and naive hESCs maintained in 5i/L/A or three alternative naive
maintenance conditions.
(H) Genome-wide CpG methylation level of all H9 samples described in (A) based on WGBS five passages after switching from 5i/L/A to the alternative naive
media. An accompanying tile-based measure of global DNA methylation is shown in Figure S3G.
See also Figure S3.
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Lee et al., 2014; Leitch et al., 2013; von Meyenn et al., 2016).
Studies in the mouse system have suggested that MEK1/2 inhibition induces global hypomethylation via impairment of DNA
methylation enzymes (Choi et al., 2017; Yagi et al., 2017). We
examined DNA methylation levels under alternative naive conditions by whole-genome bisulfite sequencing (WGBS). Overall
CpG DNA methylation levels increased from 35% in 5i/L/A
naive hESCs to 45% in AXGY(U) and >50% in a5i/L/A. These
DNA methylation levels are slightly elevated compared to the
level of DNA methylation reported in the human ICM (42%)
(Guo et al., 2014) but remain significantly lower compared to
the hypermethylated DNA signature in primed hESCs (75%)
(Figures 3H and S3G). Despite the overall increase in DNA
methylation, increased expression of HERVH integrants in alternative naive conditions was correlated with locally reduced
methylation levels (Figure S3H). In addition, DNA methylation
at imprinted DMRs was depleted under all examined conditions
(Figure S3I). This may be explained by the fact that these maintenance experiments were performed in naive hESCs that were
derived from the primed state in 5i/L/A, which is known to cause
imprint erasure within four passages (Theunissen et al., 2016).
Inhibition of other enzymes in the FGFR-RAF-MEK-ERK
pathway also sustains naive human pluripotency
The above results indicate that the pan-RAF inhibitor AZ628 can
maintain key molecular features of naive human pluripotency in
combination with TNKS, PKC, and ROCK inhibitors (XGY). Since
AXGY promoted more robust expansion of naive cells compared
to 5i/L/A, we asked whether any of the other hit compounds from
our high-throughput screens could also sustain naive human
pluripotency under these conditions. Naive hESCs were derived
from the primed state in 5i/L/A and switched to serum-free media
supplemented with XGY and the commercially available hit compounds (Tables S2 and S3). We also included 9 additional compounds that have a shared target annotation as the remaining hit
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compounds from our screens for which commercial vendors
were unavailable (Figure S4A). In addition to AZ628, the only
compounds that robustly sustained CD75/SUSD2-positive cells
over multiple passages were the FGFR inhibitor PD166866 and
the ERK inhibitor GDC-0994. While the MAPK14 (p38) inhibitor
Semapimod supported some double-positive cells, these cells
displayed very limited proliferation (Figure S4B). Thus, the only
hit compounds that could efficiently replace MEK1/2 inhibitors
during the long-term maintenance of naive human pluripotency
inhibit either upstream (FGFR, RAF) or downstream (ERK1/2) kinases (Figure 4A). Titration experiments revealed that 1 mM of
FGFR inhibitor was sufficient to maintain expression of naivespecific transcripts, while the ERK inhibitor was more effective
at 5 mM (Figure 4B; Figure S4C). We confirmed by flow cytometry
that these inhibitors not only maintained homogeneous CD75/
SUSD2 expression but also biallelic X-linked MECP2 fluorescent
reporter activity (Figures 4C and 4D).
We then sought to determine whether naive hPSCs maintained
with the FGFR inhibitor PD166866 (FXGY) or ERK inhibitor GDC0994 (GXGY) reside in a similar state as those maintained in
AXGY. Retention of canonical naive markers in the alternative
naive maintenance conditions was corroborated by RNA-seq
analysis, which also showed negligible expression of primed
markers (Figures 4E and 4F; Table S4). Transfer from 5i/L/A to
AXGY, FXGY, or GXGY captured the cells in a pre-implantation
EPI identity, while continuous treatment with a MEK inhibitor
(PXGY) drove them toward an ICM identity (Figure 4F). Similar results were obtained by comparison to cynomolgus macaque embryo stages (Nakamura et al., 2016), although the GXGY condition clustered more closely with macaque ICM (Figure S4D).
AXGY, GXGY, and FXGY displayed a modest increase in HERVH
integrants, while all naive maintenance conditions showed strong
activation of SVA-D integrants (Figures 4G and 4H). Global DNA
methylation was slightly elevated in all four XGY-based naive media compared to 5i/L/A but remained substantially reduced

Figure 4. Inhibition of other enzymes in the FGFR-RAF-MEK-ERK pathway also maintains naive human pluripotency
(A) Experimental scheme for extended maintenance assays to evaluate the efficacy of FGFR1, RAF, MEK, and ERK inhibitors in the presence of TNKS, PKC, and
ROCK inhibition (XAV/Gö/Y).
(B) Quantitative gene-expression analysis for the naive-specific transcripts KLF17 and DNMT3L in the titration experiment shown in Figure S4C. PXGY (PD03XGY) and AXGY (AZ628-XGY) are included as controls. Error bars indicate mean ± SD of three technical replicates.
(C) Phase-contrast images (top) and flow-cytometry analyses using naive-specific CD75 and SUSD2 antibodies (bottom) in H9-naive hESCs that were switched
from 5i/L/A to the four alternative naive maintenance media for two additional passages. Data are representative of two biological replicates. The scale bar
depicts 250 mm.
(D) Phase-contrast images (top) and flow-cytometry analyses (bottom) of naive WIBR3 MECP2-GFP/tdTomato reporter hESCs that were derived from the primed
state in 5i/L/A and thereafter maintained in the four alternative naive maintenance media for two passages. The scale bar depicts 250 mm.
(E) Expression heatmap of selected naive and primed-specific markers in H9 hESCs for the alternative naive maintenance conditions described in (C). Gene
expression was compared to H9 mTeSR1 and 5i/L/A samples previously analyzed in Figure 3 and an additional H9 mTeSR1 sample (mTeSR1_2).
(F) UMAP dimension reduction analysis of scRNA-seq data representing the ICM, Pre-EPI, and Post-EPI from 3D-cultured human embryos (Xiang et al., 2020)
compared to the naive and primed samples described in (E). Clusters are drawn to indicate in vivo samples as shown in Xiang et al. (2020). A time-course RNA-seq
analysis of naive hESCs undergoing capacitation into a formative pluripotent state (Rostovskaya et al., 2019) was also integrated into this UMAP.
(G) Heatmap indicating expression of individual HERVH integrants in primed H9 hESCs and naive hESCs maintained in 5i/L/A or four alternative naive maintenance conditions as described in (E).
(H) Heatmap indicating expression of individual SVA_D integrants in H9 primed hESCs and naive hESCs maintained in 5i/L/A or four alternative naive conditions
as described in (E).
(I) Genome-wide CpG methylation level of all H9 samples described in (C) based on whole-genome bisulfite sequencing five passages after switching from 5i/L/A
to the four alternative naive maintenance conditions. Data were compared to the H9 mTeSR1 sample previously analyzed in Figure 3H.
(J) Western blot analysis for p-MEK1/2, total MEK1/2, p-ERK1/2, total ERK1/2, and b-actin (loading control) protein levels in H9-naive hESCs derived from the
primed state in 5i/L/A and switched to four alternative naive conditions.
See also Figure S4 and Table S3.
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compared to the primed state (Figure 4I; Figure S4E). Furthermore, western blotting revealed increased p-ERK levels in
AXGY, GXGY, and FXGY relative to PXGY (Figure 4J). Notably,
GDC-0994 is known not to alter the phosphorylation of cellular
ERK1/2 (Basken et al., 2018; Pegram et al., 2019). We conclude
that inhibition of FGFR, RAF, MEK, or ERK can sustain bona
fide features of naive human pluripotency despite variable levels
of ERK phosphorylation. However, the only conditions that were
capable of maintaining naive hESCs in a human ICM-like state
were those that included a direct MEK inhibitor (5i/L/A and PXGY).
While naive hPSCs are not directly responsive to embryonic
lineage inductive cues, they can be re-adapted to primed culture
conditions (a process called ‘‘re-priming’’) (Sahakyan et al.,
2017; Theunissen et al., 2016) or transitioned into a lineagecompetent formative state upon treatment with the TNKS inhibitor XAV939 (Rostovskaya et al., 2019). Naive hESCs derived in
5i/L/A and switched to three alternative maintenance media
(AXGY, GXGY, or FXGY) acquired a primed morphology and
activated the primed-specific cell-surface marker CD90 upon
treatment with mTeSR1 media within two passages (Figures
S4F and S4G). Furthermore, they downregulated naive-specific
transcripts and activated formative markers during a 10-day
capacitation experiment (Figure S4H). Consistent with their
more advanced identity relative to human EPI development
and a previously published capacitation time course (Figure 4F),
naive hESCs maintained in AXGY showed more robust induction
of formative markers compared to 5i/L/A (Figure S4H). Hence,
naive hESCs maintained in the absence of a direct MEK inhibitor
remain competent to re-enter the primed pluripotent state.
Since long-term culture in 5i/L/A has been associated with
genomic instability (Di Stefano et al., 2018; Pastor et al., 2016;
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Theunissen et al., 2014), we performed karyotyping on naive
cells that were derived in 5i/L/A and switched to alternative naive
maintenance conditions. Naive hESCs that were continuously
maintained in 5i/L/A contained various chromosomal rearrangements by passage 10. In contrast, a normal karyotype was maintained in naive hESCs that were switched from 5i/L/A to AXGY or
FXGY while a small subset of abnormal cells was observed in
either PXGY or GXGY (Figure S4I). Hence, transfer to XGY-based
naive maintenance media may enhance the genomic stability of
naive hESCs, although subclonal aneuplodies were still
observed in some of the alternative maintenance conditions.
We also verified that these cells maintained homogeneous
expression of CD75 and SUSD2, indicating that naive hESCs
can be maintained in the absence of a direct MEK inhibitor during
extended culture (Figure S4J).
Dual MEK and ERK inhibition promotes efficient primedto-naive resetting in combination with activin A
Finally, we examined whether the alternative naive maintenance
formulations identified by our screens are also capable of
inducing naive pluripotency in primed hESCs (Figure 5A; Figure S5A). H9 primed hESCs were seeded on MEFs and treated
with 5i/L/A or alternative media and the expression of naive-specific cell-surface markers was examined by flow cytometry.
Remarkably, CD75/SUSD2 double-positive cells were observed
only upon treatment with 5i/L/A (Figure 5B; Figure S5B). This
suggests that the use of a MEK inhibitor in the 5i/L/A cocktail
is critical for inducing naive pluripotency, but neither MEK nor
ERK inhibition is sufficient to induce CD75/SUSD2 double-positive cells in combination with TNKS, PKC, and ROCK inhibitors
(XGY). This led us to investigate whether the use of multiple FGF

Figure 5. Examining the signaling requirements for primed-to-naive resetting
(A) Experimental scheme for evaluating the efficacy of alternative naive maintenance media to induce naive pluripotency in primed hESCs. Successful induction of
naive pluripotency was assessed by flow cytometry for the naive-specific cell-surface markers CD75 and SUSD2 at the end of P1.
(B) Flow-cytometry analyses for naive-specific cell-surface markers CD75 and SUSD2 at the end of P1 of primed-to-naive conversion using H9 hESCs in 5i/L/A
and four alternative naive maintenance conditions. Data are representative of two biological replicates.
(C) Phase-contrast images (top) and flow-cytometry analysis for naive-specific cell-surface markers CD75 and SUSD2 (bottom) in H9 primed hESCs upon
treatment with XAV939, Gö6983, and Y-27632 (XAV/Gö/Y) together with the MEK inhibitor PD0325901 and the ERK inhibitor GDC-0994 (PXGGY) at the end of P1.
Data are representative of two biological replicates. The scale bar depicts 250 mm.
(D) UMAP dimension reduction analysis of single cell RNA-seq data representing the ICM, Pre-EPI, and Post-EPI from 3D-cultured human embryos (Xiang et al.,
2020) compared to naive hESCs that were derived in PXGGY at P1 and P8 or PXGGY+activin A (PXGGY/A) at P2. Expression data were compared to H9 mTeSR1
and 5i/L/A samples previously analyzed in Figure 3. Clusters are drawn to indicate in vivo samples as shown in (Xiang et al., 2020). A time-course RNA-seq
analysis of naive hESCs undergoing capacitation into a formative pluripotent state (Rostovskaya et al., 2019) was also integrated into this UMAP.
(E) Expression heatmap of selected naive and primed-specific markers in H9 hESCs for the primed-to-naive conversion conditions described in Figure 5C and
Figure 5F. Naive hESCs derived in PXGGY were examined at the end of P1 and P8. We also examined naive hESCs that were derived in PXGGY/A and subsequently maintained in the presence or absence of activin A for two passages (PXGGY-A) in two biological replicates each. Expression data were compared to
H9 mTeSR1 and 5i/L/A samples previously analyzed in Figure 3.
(F) Flow-cytometry analysis using antibodies for the naive-specific cell-surface markers CD75 and SUSD2 in H9 primed hESCs upon treatment with 5i/L/A,
PXGGY, and PXGGY/A at day 10 (top) and at the end of P1 (bottom) of primed-to-naive resetting. Data are representative of two biological replicates.
(G) Alkaline phosphatase (AP) staining of H9 hESCs after two passages of primed-to-naive conversion in 5i/L/A and PXGGY/A. Data are representative of two
biological replicates.
(H) Genome-wide CpG DNA methylation level of H9-naive hESCs that were converted in 5i/L/A or PXGGY/A at P5. We also examined naive hESCs that were
derived in PXGGY/A and maintained for four additional passages in the absence of activin A. Data were compared to the H9 mTeSR1 and 5i/L/A samples
previously analyzed in Figure 4I.
(I) Western blot analysis for p-ERK1/2, total ERK1/2, and b-actin (loading control) protein levels in H9 primed hESCs treated with indicated media.
(J) Flow-cytometry analysis using antibodies for the naive-specific cell-surface markers CD75 and SUSD2 to assess the effect of MEK inhibitor PD0325901
titration during primed-to-naive resetting of H9 primed hESCs in PXGGY/A medium at the end of P1.
(K) Flow-cytometry analysis using antibodies for the naive-specific cell-surface markers CD75 and SUSD2 during primed-to-naive resetting of H9 primed hESCs
by various combinations of FGF pathway inhibitors at the end of P1. Data are representative of two biological replicates.
See also Figure S5 and Table S3.
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pathway inhibitors might facilitate primed-to-naive resetting
together with XGY. While some CD75/SUSD2 double-positive
cells were observed upon dual inhibition of RAF and either
MEK or ERK, these conditions were cytotoxic (data not shown).
In contrast, more robust induction of double-positive cells was
observed upon dual inhibition of MEK and ERK (Figure 5C). We
refer to this naive induction cocktail as PXGGY for PD0325901
(MEKi), XAV939 (TNKSi), Gö6983 (PKCi), GDC-0994 (ERKi),
and Y-27632 (ROCKi) (Table S3).
We proceeded to further characterize naive hESCs derived in
PXGGY. While these cells lacked the defined colony morphology
observed in 5i/L/A, they acquired a pre-implantation EPI identity
within one passage and further passaging resulted in transition
toward an ICM-like state (Figures 5D and 5E; Table S4). They
also maintained expression of naive-specific cell-surface
markers during extended passaging (Figure S5C) and displayed
a normal karyotype at P14 (Figure S5D). We also confirmed that
PXGGY induced biallelic MECP2 reporter activity (Figure S5E).
However, the efficiency of CD75/SUSD2 double-positive cells
within the first 10 days of conversion remained low, leading us
to examine whether provision of additional cytokines might facilitate the primed-to-naive transition. An intriguing candidate is recombinant activin A, which was included in the 5i/L/A cocktail in
order to enhance cell survival during primed-to-naive resetting
(Theunissen et al., 2014). Indeed, addition of activin A to PXGGY
(PXGGY/A) enhanced naive conversion efficiency, resulting in
accelerated reprogramming kinetics as measured by flow cytometry on day 10 and colony formation efficiency at P2 (Figures
5F and 5G). Naive hESCs derived in PXGGY/A acquired a preEPI identity within two passages (Figure 5D) and activin A could
be withdrawn (PXGGY-A) without adversely affecting the
expression of key naive markers (Figure 5E). Naive hESCs
derived in PXGGY/A underwent a similar global reduction in
DNA methylation and imprint erasure as those derived in 5i/L/
A, which is likely attributable to the inclusion of a direct MEK inhibitor (Figure 5H; Figure S5F).
Recent studies from our laboratory and others have shown
that naive hPSCs have an enhanced potential for extraembryonic differentiation and can give rise to human trophoblast
stem cells (hTSCs) (Castel et al., 2020; Cinkornpumin et al.,
2020; Dong et al., 2020; Guo et al., 2021; Io et al., 2021). Naive
hESCs that were derived in PXGGY/A and maintained without
activin A for two passages acquired a typical hTSC-like
morphology and displayed activation of the hTSC-specific cellsurface markers EGFR and ITGA6 upon treatment with hTSC
media (Okae et al., 2018) (Figures S5G and S5H). They also upregulated the primed-specific cell-surface marker CD90 upon
re-priming in mTeSR1 media (Figures S5G and S5I). Hence,
naive hESCs derived in PXGGY/A respond in comparable
manner to trophoblast and re-priming conditions as those
derived in 5i/L/A. We also confirmed that naive hESCs derived
in PXGGY/A could be switched to the three alternative MEKi-independent maintenance media (AXGY, GXGY, and FXGY), while
sustaining the expression of naive-specific cell-surface markers
(Figures S5J and S5K) and their trophoblast potential (Figures
S5J and S5L).
Treatment of primed hESCs with the naive induction cocktails 5i/
L/A, PXGGY, or PXGGY/A strongly reduced p-ERK levels within 24
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h, while p-ERK levels were maintained or only partially reduced
upon treatment with alternative naive maintenance media that
failed to induce CD75/SUSD2 double-positive cells (Figure 5I).
These results suggest that the use of a direct MEK inhibitor is
necessary, but not sufficient, to achieve full suppression of pERK in primed hESCs and facilitate the transition to naive pluripotency. Consistent with this interpretation, titration or removal of the
MEK inhibitor rapidly compromised reprogramming efficiency using the PXGGY/A cocktail (Figure 5J). However, we considered
whether it might be possible to bypass the use of a direct MEK inhibitor during primed-to-naive resetting by combining other FGF
pathway inhibitors with activin A. Indeed, heterogeneous induction
of some CD75/SUSD2 double-positive cells was observed by
treating primed hESCs with the FGFR inhibitor PD166866 in the
presence of XGY and activin A (Figure 5K). Furthermore, several
combinations of FGF pathway inhibitors enabled more robust induction of naive cells, including FGFRi+RAFi, FGFRi+ERKi, and
RAFi+ERKi (Figure 5K). These combinations were also able to
induce MECP2-GFP/tdTomato double-positive cells, although
conversion kinetics were not as efficient as in PXGGY/A (Figure S5M). Hence, the use of a direct MEK inhibitor does not appear
to be absolutely required for primed-to-naive resetting but can be
circumvented by combining other FGF pathway inhibitors in an
optimized signaling environment (i.e., containing TNKS, PKC,
ROCK inhibitors, and recombinant activin A).
DISCUSSION
The past decade has witnessed substantial interest in the isolation of naive hPSCs that correspond to pluripotent cells in the human pre-implantation embryo. Significant progress has been
made toward capturing bona fide naive hPSCs by primed-tonaive resetting (Guo et al., 2017; Takashima et al., 2014; Theunissen et al., 2014), deriving naive hESCs directly from isolated
ICM cells (Guo et al., 2016), and reprogramming somatic cells
to pluripotency under naive conditions (Bredenkamp et al.,
2019b; Giulitti et al., 2019; Kilens et al., 2018; Liu et al., 2017;
Wang et al., 2018). However, a detailed understanding of the
signaling requirements for inducing and maintaining naive human pluripotency has remained elusive. In an effort to expand
the known repertoire of factors regulating naive human pluripotency, we performed high-throughput chemical screening using
a library of 3,000 well-annotated compounds (Canham et al.,
2020) to identify alternative compounds that can maintain naive
hESCs in the absence of MEK and GSK3 inhibitors that are
commonly included in naive stem cell protocols.
Our results demonstrate that MEK inhibitors can be replaced
by inhibitors of both upstream (FGFR1, RAF) and downstream
(ERK) kinases during the maintenance of naive human pluripotency. The most robust expansion of naive hESCs was attained
in combination with TNKS, PKC, and ROCK inhibitors (XGY), in
agreement with recent work from the Smith laboratory (Bredenkamp et al., 2019a, 2019b). Naive hESCs maintained by FGFR,
RAF, or ERK inhibitors displayed multiple hallmarks of naive human pluripotency, including OCT4-DPE-GFP activity, biallelic Xlinked reporter activity, and expression of key naive pluripotency
genes. Surprisingly, ERK phosphorylation was stimulated in
naive hESCs maintained with the RAF inhibitor AZ628 (AXGY)
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Figure 6. Distinct signaling requirements for inducing and maintaining naive human pluripotency
Model summarizing the main findings from this study: dual MEK and ERK inhibition promotes efficient primed-to-naive resetting in combination with
TNKS, PKC, ROCK inhibitors, and activin A (PXGGY/A). These p-ERKLOW
naive hESCs resemble previously described 5i/L/A naive hESCs (Theunissen
et al., 2016; Theunissen et al., 2014) and exhibit a human ICM-like identity
based on comparison to 3D-cultured human embryos (Xiang et al., 2020). They
can transition into a pre-implantation EPI state with elevated levels of ERK
phosphorylation in the presence of RAF, TNKS, PKC, and ROCK inhibitors
(AXGY). These cells retain expression of typical naive markers but also display
increased levels of global DNA methylation and HERVH transcription. Global
DNA methylation and HERVH transcription are further increased in the primed
pluripotent state, which corresponds to the post-implantation epiblast at E12–
14.

or FGFR inhibitor PD166866 (FXGY). Interestingly, however,
modulation of these different nodes in the FGF pathway isolated
naive hESCs along progressive stages of early development:
while the inclusion of a direct MEK inhibitor in 5i/L/A or PXGY
captured naive cells in a human ICM-like state, naive cells maintained in the absence of MEK inhibitors progressed to a pre-implantation EPI identity and displayed increased expression of
HERVH integrants (Figure 6).
The alternative naive maintenance formulations were unable to
induce naive pluripotency in primed hESCs, suggesting that
complete MEK/ERK inhibition achieved by the 5i/L/A cocktail
is critical for primed-to-naive resetting. Dual inhibition of MEK
and ERK in the presence of PKC, TNKS, and ROCK inhibitors
provided an alternative naive induction cocktail, which we refer
to as PXGGY. When combined with activin A, this cocktail accelerated the activation of naive-specific cell-surface markers and
biallelic X-linked reporter activity compared to 5i/L/A. However,
naive hESCs generated with PXGGY/A still incurred imprint
erasure, likely due to the inclusion of a direct MEK inhibitor
(Choi et al., 2017; Yagi et al., 2017). In the presence of XGY
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and activin A naive cell induction could also be achieved by
several other combinations of FGF pathway inhibitors, including
FGFRi+RAFi, FGFRi+ERKi, and RAFi+ERKi, but reprogramming
kinetics were reduced compared to PXGGY/A. This may provide
a path to generate naive hESCs in the absence of direct MEK inhibition, although it remains to be determined whether these
cells meet stringent criteria for naive pluripotency.
This work raises several questions for future investigation.
First, it remains unclear how ERK phosphorylation is stimulated
in the presence of upstream FGF pathway inhibitors. A potential
mechanism involves the loss of negative feedback regulation
(Lake et al., 2016), which could be explored by perturbing the
expression of members of the DUSP and Sprouty families. Our
results also raise the possibility that upstream FGF pathway
inhibitors may stimulate naive human pluripotency through
mechanisms that are located upstream of ERK, for example by
blocking other RAF or MEK targets. A more complete understanding of the underlying biochemical mechanisms will likely
require examination of the global phosphoproteome in naive
hESCs maintained with different FGF pathway inhibitors. Second, the alternative naive maintenance conditions resulted in a
progression in pre-implantation epiblast identity and increased
HERVH expression compared to MEK inhibitor-containing naive
media. This suggests that the alternative naive hESCs may be
more responsive to embryonic lineage cues, while their
enhanced proliferation may be beneficial for efforts to improve
the contribution of naive hESCs to interspecies chimeras (Wu
et al., 2016) or human blastocyst-like structures (Yu et al.,
2021). Third, it will be important to evaluate which combination
of naive induction and maintenance conditions best preserves
the long-term genomic integrity of naive hESCs, while simultaneously mitigating the erosion of parent-specific DNA methylation marks at imprinted loci.
Finally, we wish to emphasize that we took a deliberately minimalistic approach by screening for factors that induce and maintain naive human pluripotency in the presence of few other
signaling inputs. It may be possible to further improve on aspects
of the naive phenotype by testing other permutations among the
compounds identified in our screen or providing additional factors. Furthermore, our studies were performed on naive hESCs
induced from pre-existing primed hESC lines. Whether similar
signaling principles apply during naive hPSC derivation from blastocysts or somatic cells will require further examination. For
example, it is conceivable that naive hPSCs may be isolated
under less stringent conditions from pre-implantation embryos
or reprogramming intermediates that already exist in a globally hypomethylated state. The high-throughput screens presented in
this study expand the chemical toolkit available to capture
hPSC states corresponding to discrete stages of embryogenesis.
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wustl.edu).
Materials availability
Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Thorold Theunissen (t.
theunissen@wustl.edu).
Data and code availability
The RNA-seq and WGBS data are available under GEO: GSE153215.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and culture conditions
Primed hESCs (H9, WIBR3, WIBR3 OCT4-DPE-GFP, WIBR3 MECP2-GFP/tdTomato) were cultured in mTeSR Plus (STEMCELL
Technologies, 100-0276) on Matrigel (Corning, 354277) coated wells and passaged using ReLeSR (STEMCELL Technologies,
05872) or dissociated with Dispase (STEMCELL Technologies, 07923) and passaged by cutting colonies into small, uniform squares
with StemPro EZPassage Stem Cell Passaging Tool (GIBCO, 23181010) every 4 to 6 days. Primed hESCs were fed with fresh media
every second day and were cultured in 5% CO2 and 20% O2 at 37 C. Naive hESCs were cultured in 5% CO2 and 5% O2 at 37 C in 5i/
L/A or alternative culture conditions. 5i/L/A media were prepared by combining N2B27 and the following small molecules and cytokines as previously described (Theunissen et al., 2014): 1 mM PD0325901 (Stemgent, 04-0006), 1 mM IM-12 (Enzo, BML-WN102),
0.5 mM SB590885 (Tocris, 2650), 1 mM WH-4-023 (A Chemtek, H620061), 10 mM Y-27632 (Peprotech, 1293823), 20 ng/mL recombinant human LIF (PeproTech, 300-05) and 10 ng/mL Activin A (Peprotech, 120-14). 500 mL N2B27 was generated by combining:
240 mL DMEM/F12 (GIBCO, 11320), 240 mL Neurobasal (GIBCO, 21103), 5 mL N2 100X supplement (GIBCO, 17502), 10 mL B27
50X supplement (GIBCO, 17504), 1X GlutaMAX, 1X MEM NEAA (GIBCO, 11140), 0.1 mM b-mercaptoethanol (Millipore Sigma,
8.05740), 1% penicillin-streptomycin, and 50 mg/ml BSA Fraction V (GIBCO, 15260). All tissue culture experiments were performed
in 6-well plates unless stated otherwise. Media were filtered using a 0.22 mm filter and cell lines were regularly tested for mycoplasma
contamination. Detailed information on conditions used for defining alternative naive induction and maintenance media can be found
in the Method details below and in Table S3.
METHOD DETAILS
High-throughput chemical screening
For high-throughput screening, we used WIBR3 OCT4-DPE-GFP+ naive hESCs generated with inducible KLF2 and NANOG transgenes, as described previously (Theunissen et al., 2014). These cells were maintained in 1 mM PD0325901, 1 mM CHIR99021, and
2 mg/ml DOX (Sigma) (2i/DOX). For compound screening in presence of 2i/Y, 3,000 OCT4-DPE-GFP+ naive hESCs were seeded
per well in vitronectin-coated 384 well plates in serum-free N2B27 media supplemented with 1 mM PD0325901, 1 mM CHIR99021,
and 10 mM Y-27632. The next day individual compounds from the Novartis Mechanism of Action (MoA) library were applied at two
concentrations (2.5 mM and 5 mM) in duplicate using an Echo 550 Acoustic Liquid Handler (Labcyte), and compounds were refreshed
on day 4. Images were analyzed on day 5 post-DOX withdrawal using a Yokogawa Cell Voyager 7000 High-Content Imaging System
in confocal mode using a 10x dry (NA = 0.45) objective lens using four fields per well that provided for full well coverage. While the
screen was performed at two concentrations (2.5 mM and 5 mM), the lower concentration yielded few additional hits. Hit compounds
were validated in 384 well plates across an 8-point concentration range in duplicates. For high-throughput screening in absence of 2i,
384 well plates were pre-coated with mitotically inactivated mouse embryonic fibroblasts (MEFs) to improve viability. Pilot assays
revealed that a maximal Z’-factor was obtained in absence of 2i by performing image acquisition on day 7 post-DOX withdrawal
and using a seeding density of 800 OCT4-DPE-GFP+ naive hESCs per 384 well. Naive hESCs were seeded in serum-free N2B27
media supplemented with 10 mM Y-27632 alone (N2B27/Y) or upon addition of 2 mM XAV939 (XAV/Y) or 2 mM Gö6983 (Gö/Y).
The next day individual compounds from the Novartis MoA library were added at 5 mM concentration using the Echo 550 Acoustic
Liquid Handler and compounds were refreshed on days 3 and 6. Images were acquired using the Yokogawa Cell Voyager 7000 on
day 7 and analyzed as described above. Hit compounds were validated in 384 well plates across an 8-point concentration range in
duplicate. A detailed explanation of the multi-parametric analysis of high-content imaging data in this study is provided below under
‘‘Quantification and Statistical Analysis.’’
Defining alternative naive maintenance media
To define the activity of selected hit compounds during extended naive culture, naive hESCs derived from the primed state and
maintained in 5i/L/A were dissociated with Accutase (Thermo Fischer Scientific, A1110501) and 1.5 3 105 single cells were seeded
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in 5i/L/A media on MEF-coated plates. After 24 hours, 5i/L/A media were switched to experimental maintenance conditions to validate hits from the screen. After 4-6 days the cells were split in a 1:2 or 1:3 ratio and further maintained for 4-6 days before analysis
by FACS, qRT-PCR, AP staining, and/or RNA-seq. 5i/L/A media in which the MEK inhibitor PD0325901 was replaced with 5 mM
AZ628 are represented as alternative 5i/L/A (a5i/L/A). FXGY, AXGY, AXGYU, PXGY, and GXGY media were prepared in serumfree N2B27 media supplemented with 1 mM PD166866, 5 mM AZ628, 5 mM AZ628 and 1 mM UNC0638, 1 mM PD0325901, and
5 mM GDC-0994, respectively, together with 2 mM XAV939, 2 mM Gö6983, and 10 mM Y-27632. During these assays cells were
fed with fresh media every second day and cultured in 5% O2, 5% CO2 at 37 C. Detailed information on conditions used for
defining alternative naive maintenance media can be found in Table S3.
Primed-to-naive resetting
For primed-to-naive resetting experiments, primed hESCs were dissociated into single cells using TrypLE Express (GIBCO, 12604),
washed in fibroblast medium [DMEM (Millipore Sigma, #SLM-021-B) supplemented with 10% FBS (HyClone, SH30396.03, 1X GlutaMAX (GIBCO, 35050), and 1% penicillin-streptomycin (GIBCO, 15140)] and 2 3 105 single primed hESCs were seeded on mitomycin C-inactivated mouse embryonic fibroblast (MEF) feeder cells coated 6 well plates in 3-4 mL mTeSR1 supplemented with
10 mM Y-27632. Two days later, medium was switched to either 5i/L/A or experimental induction media and maintained for 1012 days. Cells at this stage were considered at passage zero. Cells were then split in a 1:2 or 1:3 ratio every 4-6 days as single cells
using Accutase (Thermo Fischer Scientific, A1110501). PXGGY media were prepared in serum-free N2B27 media supplemented with
1 mM PD0325901, 2 mM XAV939, 2 mM Gö6938, 2.5 mM GDC-0994, and 10 mM Y-27632. PXGGY/A media were prepared in PXGGY
supplemented with 10 ng/ml Activin A. During these assays cells were fed with fresh media every second day and cultured in 5% O2,
5% CO2 at 37 C. Detailed information on the conditions used for defining alternative naive induction media can be found in Table S3.
Flow cytometry
Primed hESCs were single-cell dissociated using TrypLE Express, while Accutase was used for naive hESCs. Cells were resuspended in fibroblast medium and centrifuged. Cell pellets were washed in 5 mL ice-cold PBS. The cells were then resuspended
in 100 mL fresh ice-cold FACS buffer (PBS supplemented with 5% FBS), and incubated with antibodies for 30 minutes on ice in
the dark. The following antibodies were used: anti-SUSD2-PE (1:100), anti-CD75-eFluor 660 (1:100), anti-CD90-PE (1:100), antiITGA6-FITC (1:100) and EGFR-APC (1:25). Post-incubation the cells were washed once with 1 mL ice-cold PBS, resuspended in
fresh 500 ml FACS buffer, and passed through a 0.35 mm cell strainer into round bottom FACS tubes (Corning, #352235). Flow cytometry was performed using a BD LSRFortessa X-20 and the data were analyzed using the FlowJo software.
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated using the E.Z.N.A. total RNA kit I and cDNA synthesis was performed from total RNA using the high-capacity
cDNA reverse transcription kit (Applied Biosystems, 4368814). qRT-PCR was performed using PowerUp SYBR Green Master Mix
(Applied Biosystems, A25743) on the StepOnePlus Real-Time PCR System (Applied Biosystems). Gene expression was normalized
to RPLP0 and analyzed using the DCt method. Error bars represent the standard deviation (SD) of the mean of technical replicates.
Alkaline phosphatase (AP) staining
AP staining was performed following the manufacturer’s instructions using the Leukocyte Alkaline Phosphatase Kit (Sigma, 86R,
1KT). For AP staining cells were seeded at equal density in in 6-well plates and passaged in the same ratio for all conditions.
Post-staining cells were allowed to dry overnight in the dark and scanned using HP Color Laser Jet Managed printer/scanner
(MFP E67650).
Imaging
The imaging of H9 and WIBR3 hESCs was performed in live conditions within culture media. For WIBR3 MECP2-GFP/tdTomato
hESCs the medium was aspirated, cell were washed twice with PBS, and imaged in 1 mL of PBS. All images were captured at
10X magnification on a Leica DMi8 microscope.
Karyotyping
For G-banded karyotyping naive hESCs were cultured in 6-well plates in 5i/L/A or alternative maintenance media (FXGY, AXGY,
PXGY and GXGY) or primed-to-naive resetting medium (PXGGY) for the indicated passage numbers. Cells were then seeded in
T25 flasks and karyotyped by the Cytogenetics and Molecular Pathology facility of Washington University in St. Louis using standard
methods.
Immunoblotting
For western blot analysis of protein expression in primed hESCs, a semi-confluent well was treated with 4 mL of mTeSR1+ROCKi, 5i/
L/A, or alternative naive maintenance and induction media for 20 hours. Post-treatment, the cells were washed with 1 mL of cold PBS
twice and solubilized in 300 mL of RIPA buffer (Cell Signaling, #9806) with phosphatase inhibitor (ThermoFischer Scientific, #A32957)
on ice for 20 min. For naive hESCs, a single cell dissociation was prepared using Accutase and single cells were transferred to
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Gelatin-coated plates for 45 minutes at 37 C. This is a feeder-depletion step, which allows the MEFs to attach to the plate surface,
while hESCs remain in the media. The media were then collected in 15 mL tubes and centrifuged. Cell pellets were washed twice with
2 mL cold PBS and solubilized in 300 mL RIPA buffer on ice for least 20 min. The lysates from both primed and naive cells were
collected after centrifugation. Protein concentration was measured by the Bradford assay (Biorad, #5000006). 20 mg of protein samples were loaded on an SDS-PAGE gel and transferred to a nitrocellulose membrane for immunoblotting. Afterward, the membrane
was blocked with 5% nonfat milk (Bio-Rad, #170-6404) at room temperature for 1 hour in TBST (20 mM tris-HCl, pH 7.6, 137 mM
NaCl, and 0.1% Tween 20), and incubated with a primary antibody [b-actin (1:2000), ERK1/2 (1:3000), p-ERK1/2 (1:1500), MEK1/
2 (1:2500) and p-MEK1/2 (1:1500)] overnight at 4 C, followed by a secondary antibody (1:2000) conjugated with horseradish peroxidase for 45 min at RT. Protein bands on the membrane were detected by the ECL detection system (Biorad #1705060). Immunoblots
were imaged and analyzed using the Invitrogen iBright Imaging CL1000 System.
RNA sequencing
Total RNA was isolated from 2 million naive or primed cells using the E.Z.N.A. total RNA kit I. Library construction was performed
using the SMARTer Directional cDNA Library Construction Kit (Clontech, 634933). Libraries were sequenced on an Illumina HiSeq3000 1X50 or NovaSeq S4 2x150 platform at the Genome Technology Access Center at Washington University School of Medicine in St. Louis
Whole genome bisulfite sequencing
Genomic DNA was extracted from 2 million naive or primed cells using the DNeasy Blood and Tissue Kit (QIAGEN, Valencia, CA).
Whole Genome Bisulfite conversions were performed with 200 ng of gDNA using the EZ DNA Methylation-Gold, 50rxn kit (Fisher,
#50444294). WGBS Libraries were created using the Accel-NGS Methyl-Seq DNA Library Kit - 24 rxns (Swift Biosciences,
#30024) and Accel-NGS Methyl-Seq Dual Indexing Kit - 96rxns (Swift Biosciences, #38096). The libraries were pooled and
sequenced on 0.240 of a NovaSeq S4 flow cell (300 XP; targeting 30x WGBS coverage/120Gb per sample) at the Genome Technology Access Center at Washington University School of Medicine in St. Louis.
Re-priming of naive hESCs
For re-priming, a 70%–80% confluent culture of naive hESCs that were maintained in 5i/L/A or alternative conditions were harvested
as single cells using Accutase and seeded in a 1:2 ratio on a Matrigel-coated plate in mTeSR1 media supplemented with ROCK inhibitor Y-27632 and cultured in 5% CO2 and 20% O2 at 37 C. Y-27632 was withdrawn on the second day. Colonies with a flat
morphology resembling primed hESCs appeared within 6 days. These colonies were dissociated with TrypLE as single cells and
analyzed by FACS for the primed-specific cell surface marker CD90.
Capacitation of naive hESCs
Capacitation of naive hESCs was performed as previously described (Rostovskaya et al., 2019). Approximately 0.5 3 106 TrypLEdissociated naive hESCs were seeded in 5i/L/A or alternative naive conditions on one well of a Geltrex (Thermo Fisher, A1413201)
coated 6-well plate. After 48 hours, naive media were switched to capacitation media (N2B27 supplemented with 2 mM XAV939).
The cells were fed fresh media every 1-2 days and passaged at 70%–80% confluency (about 4-5 days) using TrypLE (GIBCO,
12604054). 10 mM of Y-27632 was added for 24 hr following passaging. Cells were analyzed for the expression of naive and
primed-specific genes by qRT-PCR after 10 days. Capacitation was performed in 5% CO2 and 5% O2 at 37 C.
Derivation of hTSCs from naive hESCs
hTSCs were derived from naive hESCs as previously described (Dong et al., 2020). Briefly, naive hESCs maintained in 5i/L/A or alternative naive media were dissociated into single cells using TrypLE. 0.5-1.0 3 106 cells were seeded in a 6-well plate pre-coated with
5 mg/mL Collagen IV and switched to 2 mL hTSC medium (Okae et al., 2018) [DMEM/F12 supplemented with 0.1 mM 2-mercaptoethanol, 0.2% FBS, 0.5% Penicillin-Streptomycin, 0.3% BSA, 1% ITS-X (GIBCO, 51500), 1.5 mg/ml L-ascorbic acid (Wako, 013–
12061), 50 ng/ml EGF (Rockland, 009–001 C26), 2 mM CHIR99021 (Stemgent, 04–0004), 0.5 mM A83-01 (BioVision, 1725), 1 mM
SB431542 (BioVision, 1674), 0.8 mM VPA (Tocris, 2815), and 5 mM Y-27632]. Cells were cultured in 5% CO2 and 20% O2 at
37 C, media were changed every 2 days, and passaged upon reaching 80%–100% confluency at a ratio of 1:2 to 1:4 using TrypLE.
Cells were analyzed by FACS for the hTSC-specific cell surface markers ITGA6 and EGFR after 5-7 passages.
QUANTIFICATION AND STATISTICAL ANALYSIS
Multi-parametric analysis of high-content imaging data
Images were analyzed using a Yokogawa Cell Voyager 7000 High-Content Imaging System. A total of 112 features were calculated
from the data and these included statistics (e.g., mean, median, total, sum, standard deviations, covariance) and maximum and minimum values of fluorescent object shape parameters (e.g., area, circumference, diameter, circularity, anisometry, and compactness)
as well as fluorescent intensity values (e.g., mean, median, total, maximum, and minimum). To determine which set of parameters
provided the most robust Zʹ-factors (a measure of statistical effect size, see below) we applied a Multi-Parametric Data Analysis
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(MPDA) algorithm to analyze these images, selecting features showing robust Zʹ-factors taken from the calculated shape and fluorescent intensity parameters. We then computed a Mahalanobis distance score (MHD) between each compound and the active
(+DOX) and negative (-DOX) control wells based on features that included area, compactness and fluorescence intensity (typically
a combination of shape parameters such as area and mean intensity provided acceptable Zʹ-factors) (Zhang et al., 1999). This provides a multivariate generalization to determine the similarity between controls (+/DOX) and compound-treated wells and distinguished objects that were likely due to cell death and phenotypes that were disparate from the desired phenotype observed in
the positive control wells (Figure S1A).
The Z’-factor is a measure of statistical effect size used to assess the robustness of a high-throughput screen based on the means
and standard deviations of both the positive and negative controls. The Zʹ-factor was calculated as:
Z0 =

3s + + 3s
jm +  m j

Where s+ = standard deviation of the MHD score for +DOX-treated wells
s- = standard deviation of the MHD score of -DOX-treated wells
m+ = average MHD score for +DOX-treated wells
m- = average MHD score for -DOX-treated wells
Hits were then called based on those sample wells showing an MHD value similar to the +DOX control wells by employing a
threshold of > 1 SD from the MHD value of the -DOX control wells in duplicate runs (Figure S1A). Additionally to further refine the
hit list, all the raw images and calculated data were visualized using TIBICO Spotfire where the images from sample wells designated
as hits could be easily compared to positive and negative control wells.
RNA-seq data analysis
RNA-seq reads were aligned to the human genome hg38 with HISAT2 version 2.2.0 (Kim et al., 2019). Gene counts were derived from
the number of uniquely aligned unambiguous reads by Subread:featureCount (Liao et al., 2014), version 1.4.6, with hg38 annotation
gencodeV31 (Harrow et al., 2012). All gene-level transcript counts were then imported into the R/Bioconductor package DESeq2
(Love et al., 2014). Transcripts with CPM > 1.0 were converted into a DESeq2 dataset and then regularized log transformed using
the rlog function from the DESeq2 package. Adjusted p values for DGE were determined by DESeq2 using the R stats function
p.adjust using the Benjamini and Hochberg correction to determine the false discovery rate with a 1.5-fold expression change
and FDR < 0.05 required to consider a gene differentially expressed. Dimension reduction using Uniform Manifold Approximation
(UMAP) and comparison with single-cell RNA-seq data was performed using the R/Bioconductor package Seurat and plotted using
the R package scatterplot3D.
Whole genome bisulfite sequencing data analysis
WGBS data were trimmed of adapters using Cutadapt version 1.2.1 (Martin, 2011), and aligned to the human genome hg38 with Bismark version 0.22.3 (Krueger and Andrews, 2011). The aligned reads were further processed with MethPipe (Song et al., 2013), and %
DNA methylation levels of CpGs on imprinted regions were compiled with the roimethstats function from MethPipe. The genomewide average % DNA methylation of CpGs was compiled on 1 kB sliding windows (offset 500 bp).
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